West Pharmaceutical Services financials
$376.63+0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $872.3M | $844.9M | $805.0M | $804.6M | $766.5M | $698.0M | $748.8M | $746.9M | $702.1M | $695.4M | $732.0M | $747.4M |
| Gross profit | $329.2M | $296.4M | $303.9M | $294.3M | $273.9M | $231.9M | $273.6M | $264.7M | $230.0M | $230.2M | $278.2M | $288.3M |
| Gross margin | 37.7% | 35.1% | 37.8% | 36.6% | 35.7% | 33.2% | 36.5% | 35.4% | 32.8% | 33.1% | 38.0% | 38.6% |
| Operating income | $191.9M | $181.1M | $175.1M | $174.5M | $158.9M | $127.6M | $169.8M | $165.7M | $129.5M | $122.8M | $160.9M | $177.3M |
| Net income | $154.0M | $138.8M | $132.1M | $140.0M | $131.8M | $89.8M | $130.1M | $136.0M | $111.3M | $115.3M | $137.0M | $161.3M |
| Net margin | 17.7% | 16.4% | 16.4% | 17.4% | 17.2% | 12.9% | 17.4% | 18.2% | 15.9% | 16.6% | 18.7% | 21.6% |
| Diluted EPS | $2.15 | $1.92 | $1.82 | $1.92 | $1.82 | $1.23 | $1.77 | $1.85 | $1.51 | $1.55 | $1.83 | $2.14 |
| EBITDA | $238.1M | $226.3M | $222.1M | $217.5M | $200.3M | $167.6M | $210.5M | $205.9M | $168.4M | $158.4M | $160.9M | $213.0M |
| Operating cash flow | $124.0M | $89.9M | $251.1M | $197.2M | $177.1M | $129.4M | $190.1M | $180.1M | $165.0M | $118.2M | $239.1M | $230.1M |
| Free cash flow | $80.8M | $47.2M | $175.0M | $133.9M | $101.9M | $58.1M | $85.2M | $98.8M | $64.8M | $27.6M | $130.4M | $134.3M |
| Diluted shares | 71.3M | 72.4M | 72.7M | 72.6M | 72.5M | 73.0M | 73.4M | 73.4M | 73.7M | 74.3M | 74.8M | 75.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $435.8M | $521.4M | $791.3M | $628.5M | $509.7M | $404.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $202.9M | $202.8M | $202.8M | $202.7M | $202.6M | $202.6M |
| Total assets | $4.08B | $4.11B | $4.27B | $4.11B | $3.95B | $3.62B |
| Total liabilities | $1.09B | $1.12B | $1.09B | $1.05B | $1.02B | $935.1M |
| Shareholders' equity | $2.99B | $2.99B | $3.18B | $3.05B | $2.93B | $2.68B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology